Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on November 15, 2024, reporting the entry into material definitive agreements to restructure its debt obligations. The filing details a Debt Exchange Agreement and a subsequent Securities Purchase Agreement with a holder of the Company's Senior Secured Convertible Notes. These transactions are contingent upon stockholder approval, which the Company intends to seek at a special meeting no later than January 31, 2025.
Key Financial Metrics and Transaction Details
- Debt Exchange: The Company agreed to exchange $22,347,543 in principal of Convertible Notes and accrued interest for 22,347 shares of Series C Convertible Preferred Stock.
- Remaining Debt: Upon consummation, the outstanding principal balance of the remaining Convertible Note is approximately $6.4 million.
- Securities Purchase: On November 20, 2024, the Company entered an agreement to issue 2,653 shares of Series C Preferred Stock in exchange for $2,652,456.76 of unsecured debt.
- Series C Preferred Stock Terms:
- Stated value: $1,000 per share.
- Dividend rate: 7.875% per annum, payable quarterly.
- Initial conversion price: $1.068 per share of common stock.
- Liquidation preference: 110% of stated value plus accrued dividends, pari passu with Series B Preferred Stock.
- Financial Covenants: The Company must maintain cash flow on a break-even basis. Certain financial tests (minimum cash of $8.0 million, market cap of $75 million) have been waived by the Holder until December 31, 2025.
Material Changes and Amendments
The filing outlines significant modifications to the Company's capital structure and existing debt instruments:
- Convertible Note Amendments: The conversion price for the remaining notes is reset to $1.068, and the maturity date is extended to December 31, 2025.
- Lucid Holdings Restriction: The Company cannot dispose of its Lucid common stock without the Holder's prior written consent.
- Management Services Agreement (MSA): All payments from Lucid under the MSA must be made in cash. Additionally, if the Company's VWAP is below the conversion price or a Triggering Event occurs, 50% of gross MSA payments received after January 31, 2025, must be set aside.
- Redemption Rights: The Company waived its right to redeem the Convertible Note while Series C Preferred Stock is outstanding. The Company retains a right to redeem Series C Preferred Stock at 132.5% of stated value plus accrued dividends.
- Authorized Shares: The Company seeks approval to increase authorized common stock from 50 million to 250 million shares.
Outlook, Risks, and Contingencies
The consummation of the Debt Exchange and Securities Purchase is subject to customary closing conditions, primarily the approval of stockholders. The Company is obligated to seek this approval quarterly until obtained. Key risks and contingencies include:
- Triggering Events: Defined events (including failure to complete a Qualified Company Optional Redemption by March 31, 2025) allow the Holder to convert Series C Preferred Stock at an "Alternate Conversion Price," which could be significantly lower than the fixed price (as low as 80% of VWAP, with a floor of $0.2136).
- Dilution: The Company must reserve shares for conversion of the Series C Preferred Stock and remaining notes, calculated using the Alternate Conversion Price, potentially resulting in significant dilution.
- Lucid Exchange Option: The Holder retains the right to exchange the remaining Convertible Note into Lucid common stock at $0.85 per share, subject to beneficial ownership limits.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties that could cause actual results to differ from expectations.
Investor Verification Checklist
- Verify the outcome of the special stockholder meeting scheduled for no later than January 31, 2025, regarding the increase in authorized shares and the issuance of Series C Preferred Stock.
- Monitor the Company's cash flow status to ensure compliance with the break-even covenant.
- Track the Company's stock price relative to the $1.068 conversion price and the $0.2136 floor to assess the risk of the Alternate Conversion Price being triggered.
- Review the status of the remaining $6.4 million Convertible Note and any potential exercise of the Lucid exchange option by the Holder.
- Confirm the Company's ability to meet the Qualified Company Optional Redemption requirement by March 31, 2025, to avoid specific Triggering Events.